CRISPR Q3: CASGEVY Revenue $99M, Up 30% QoQ; CTX310 Wins Two RMAT Designations
CRSP is trading near its 52-week low of $44.12 (11% above the low).
Summary
CRISPR reported Q3 CASGEVY revenue of $99 million, up 30% quarter-over-quarter, alongside two FDA RMAT designations for CTX310 and a $2.28 billion cash position. Phase 1b CTX310 data lands at AHA on November 9, 2026.
Key Events · Earnings and Guidance · CRSP
-
CASGEVY Revenue Reaches $99M
Third-quarter 2026 CASGEVY revenue was $99 million, up 30% quarter-over-quarter and nearly six times the third quarter of 2025; more than 750 patients have initiated treatment worldwide.
-
Q3 Net Loss $111.4M
Net loss was $111.4 million ($1.15 per share) versus $106.4 million a year ago, as R&D rose to $71.9 million from $58.9 million; collaboration expense fell to $41.3 million from $57.1 million on a larger share of CASGEVY revenue.
-
Cash Position $2.28B
Cash, cash equivalents and marketable securities totaled $2,276.6 million at September 30, 2026, up from $1,975.8 million at December 31, 2025, aided by $585.4 million of net proceeds from March 2026 convertible notes.
-
CTX310 Gets Two RMAT Designations
The FDA granted RMAT designations to CTX310 for severe hypertriglyceridemia and for elevated LDL-C, carrying Fast Track and Breakthrough Therapy benefits including eligibility for priority review and accelerated approval.
Analysis · CRSP · Life Sciences
The number that matters is CASGEVY revenue of $99 million: up 30% quarter-over-quarter and nearly six times the year-ago quarter, with more than twice as many patients treated in the first nine months of 2026 as in all of 2025. That shifts the commercial story from promise to measurable ramp, and under the 60/40 Vertex profit split, CRISPR's share of that revenue is what narrows its collaboration expense (down to $41.3 million from $57.1 million a year ago). Against a $111.4 million quarterly net loss, the $2.28 billion cash pile funds the pipeline for years without a financing. Two FDA RMAT designations for CTX310 add a regulatory accelerant ahead of Phase 1b severe hypertriglyceridemia data due at AHA on November 9, 2026 — a near-term readout that can re-rate the cardiovascular program.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 32.3% of the 2077 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRSP was trading at $49.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $44.12 to $65.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.